ArticleFrontiers in medicine2026
MAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insights.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic hepatitis B (CHB) frequently coexists with metabolic dysfunction-associated fatty liver disease (MAFLD), yet the impact of MAFLD on hepatitis B virus (HBV) replication remains incompletely understood. We aimed to investigate the association between MAFLD and HBV DNA levels and to provide biological context through integrative transcriptomic analyses. Methods: We analyzed a large retrospective cohort of patients with CHB and assessed the association between MAFLD and serum HBV DNA levels using linear regression models. HBV DNA was analyzed as a continuous outcome after log10 transformation. To provide molecular context for the clinical findings, weighted gene co-expression network analysis (WGCNA) was performed in an independent HBV liver transcriptomic dataset to identify HBV-associated host co-expression modules. These modules were subsequently characterized in independent liver transcriptomic datasets representing distinct metabolic and histological liver contexts using single-sample gene set enrichment analysis (ssGSEA). Results: MAFLD was independently associated with lower circulating HBV DNA levels. This association varied across MAFLD phenotypes, with the lowest HBV DNA levels observed in overweight- or obesity-related MAFLD. Transcriptomic analyses identified HBV-associated host co-expression programs linked to lipid and cholesterol metabolism, inflammatory signaling, and antiviral responses. Cross-cohort analyses further showed that selected modules varied across distinct metabolic and fibrotic liver contexts. Conclusions: MAFLD is associated with reduced HBV DNA levels in patients with CHB, especially in overweight- or obesity-related MAFLD. The transcriptomic findings provide complementary biological context for this clinical association and highlight metabolic and immune pathways that warrant further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.